Deschatelets Pascal's Form 4 filing
Apellis Pharmaceuticals, Inc.APLS · filed Mar 11, 2024
- Accession no.
- 0001127602-24-009368
- Filed
- Mar 11, 2024
- Trade date
- Mar 8, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.30M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deschatelets PascalCIK 0001657720 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2024 | Common Stock | MOption exerciseAcquired | +69,107 | $3.67 | +$253,622.69 | 1,185,090 | Direct | |
| Mar 8, 2024 | Common Stock | SSaleDisposed | −42,750 | $61.88F3 | −$2,645,370 | 1,142,340 | Direct | |
| Mar 8, 2024 | Common Stock | SSaleDisposed | −26,257 | $62.69F5 | −$1,646,051.33 | 1,116,083 | Direct | |
| Mar 8, 2024 | Common Stock | SSaleDisposed | −100 | $63.35 | −$6,335 | 1,115,983 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2024 | Common Stock | MOption exerciseDisposed | −69,107 | $0.00 | $0 | 106,387 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $61.30 - $62.295. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $62.30 - $63.2925. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.